“Breast Cancer DNA Strain Patents Are Invalid,” Shannon V. McCue, Esq.

A New York court has held that Myriad Genetics’ monopoly of isolated breast cancer DNA and use of that DNA in testing for breast cancer is over, ruling that Myriad’s patents encompassed products of nature that were not properly the subject of a patent.